Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Time spent above, not below, the target glucose range was associated with mortality in a study of adults with type 2 diabetes ...

Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

PsA is a chronic, inflammatory disease in and around the joints as well as the surrounding tendons and ligaments. It is ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief ...

Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the ...

Dr Bianca Ogden and Hashan De Silva share the companies and trials they find interesting in the constantly innovating biotech ...

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...